Table 1.
Summary of proportions of patients with investigator‐reported complete remission (full analysis set), by age group
| Total | ≥55 years | <55 years | |
|---|---|---|---|
| Total | n = 69 | n = 60 | n = 9 |
| CR, n (%) | 32 (46.4) | 24 (40.0) | 8 (88.9) |
| 80% CIa | (38.7‐54.1) | (31.9‐48.1) | (75.5‐100.0) |
| Cytogenetic risk | |||
| Good/intermediate | n = 48 | n = 41 | n = 7 |
| CR, n (%) | 26 (54.2) | 20 (48.8) | 6 (85.7) |
| 80% exact CIa | (45.0‐63.4) | (38.8‐58.8) | (68.8‐100.0) |
| Poor | n = 19 | n = 17 | n = 2 |
| CR, n (%) | 5 (26.3) | 3 (17.6) | 2 (100.0) |
| 80% exact CIa | (13.4‐39.3) | (5.8‐29.5) | (100.0‐100.0) |
| Not evaluated | n = 2 | n = 2 | n = 0 |
| CR, n (%) | 1 (50.0) | 1 (50.0) | ‐ |
| 80% exact CIa | (4.7‐95.3) | (4.7‐95.3) | ‐ |
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CR, complete remission; MDS, myelodysplastic syndromes.
For AML, good/intermediate cytogenetic risk = favorable, intermediate‐I and intermediate‐II risk groups; poor cytogenetic risk = adverse risk group.
For MDS, good/intermediate cytogenetic risk = good and intermediate risk groups; poor cytogenetic risk = poor risk group.
CR included both confirmed and unconfirmed responses for MDS patients.
a
Using normal approximation and CIs are expressed in percentages.